Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit

Metabolism: Clinical and Experimental

Volumn 58, Issue 4, 2009, Pages 488-491

  Weinrauch, Larry A ^a,b,c,d   Bayliss, George ^b,d   Gleason, Ray E ^d   Lee, Annette T ^e   D'Elia, John A ^a,b,d  

^a JOSLIN DIABETES CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Mt Auburn Hospital   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION;

ADULT; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN; MALE;

EID: 62349089521     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.11.006     Document Type: Article

References (21)

1. Paolisso G., Scheen A.J., Giugliano D., Sgambato S., Albert A., Varricchio M., et al. Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab. 72 (1991) 607-615
2. Paolisso G., Sgambato S., Giunta R., Varricchio M., and D'Onofrio F. Pulsatile rather than continuous glucagon infusion leads to greater metabolic derangements in insulin-dependent diabetic subjects. Diabete Metab. 16 (1990) 42-47
3. Berts A., Liu Y.J., Gylfe E., and Hellman B. Oscillatory Ca2+ signaling in somatostatin-producing cells from the human pancreas. Metabolism. 46 (1997) 366-369
4. Maiter D., Underwood L.E., Maes M., Davenport M.L., and Ketelslegers J.M. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology. 123 (1988) 1053-1059
5. Aoki T.T., Benbarka M.M., Okimura M.C., et al. Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus. Lancet 342 (1993) 525-528
6. Aoki T.T., Vlachokosta F.V., Foss M.C., and Meistas M.T. Evidence for restoration of hepatic glucose processing in type I diabetes mellitus. J Clin Invest 71 4 (1983) 837-839
7. Weinrauch L.A., Burger A.J., Aepfelbacher F., Lee A.T., Gleason R.E., and D'Elia J.A. A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetic patients with proteinuria. Metabolism 56 (2007) 1453-1457
8. Dailey G., Boden G., Creech R., Johnson D., Gleason R.E., Kennedy F.P., et al. Effects of pulsatile intravenous insulin therapy (PIVIT) on the progression of diabetic nephropathy. Metabolism 49 (2000) 1491-1495
9. Aepfelbacher F., Yeon S.B., Weinrauch L.A., D'Elia J., and Burger A.J. Effect of improved glycemic control on left ventricular structure and function in patients with type 1 diabetes mellitus. Int J Cardiol 94 (2004) 47-51
10. Weinrauch L.A., Burger A., Gleason R.E., Lee A.T., and D'Elia J.A. Left ventricular mass reduction in type 1 diabetic patients with nephropathy. J Clin Hypertens 7 (2005) 159-164
11. Weinrauch L.A., Burger A., Aronson D., Gleason R.E., Lee A.T., and D'Elia J.A. Regression of left ventricular hypertrophy in diabetic nephropathy: loss of parasympathetic function predicts response to treatment. J Clin Hypertens 8 (2006) 330-335
12. Aoki T.T., and Hammond G.S. Measurement of health status in diabetic patients. Diabetes impact measurement scales. Diabetes Care 15 (1992) 469-477
13. Jacobson A.M., de Groot M., and Samson J.A. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 17 (1994) 267-274
14. McColl E., and Eccles M.P. From the generic to the condition-specific? Instrument order effects in quality of life assessment. Med Care 41 (2003) 777-790
15. Simes R.J., Greatorex V., and Gebski V.J. Practical approaches to minimize problems with missing quality of life data. Stat Med. 17 5-7 (1998) 725-737
16. Jacobsen P.B., Davis K., and Cella D. Assessing quality of life in research and clinical practice. Oncology 16 (2002) 133-139
17. Weinrauch L.A., Bayliss G., Gleason R.E., Lee A.T., and D'Elia J.A. A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy. Metabolism 58 (2009) 492-496
18. Mehra S., Tavakaoli M., Kallinikos P.A., Efron N., Boulton A.J.M., Augustine T., et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 30 (2007) 2608-2612
19. Inzitari M., Pozzi C., Ferrucci L., Chiarantini D., Rinaldi L., Baccini M., et al. Subtle neurological abnormalities as risk factors for cognitive and functional decline, cardiovascular events, and mortality in older community-dwelling adults. Arch Int Med 168 (2008) 1270-1276
20. Boustani M., and Justiss M. Subtle neurological abnormalities and functional cognition in older adults. Arch Int Med 168 (2008) 1252-1253
21. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404 (2000) 787-790